Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel

Texto completo
Autor(es):
Mostrar menos -
Jones, Abby L. [1] ; Dhanapala, Lasangi [1] ; Baldo, Thaisa A. [2] ; Sharafeldin, Mohamed [1] ; Krause, Colleen E. [3] ; Shen, Min [1] ; Moghaddam, Shirin [4] ; Faria, Ronaldo C. [2] ; Dey, Dipak K. [5] ; Watson, R. William [6, 7] ; Andrawis, Ramez [8] ; Lee, Norman H. [9, 10] ; Rusling, James F. [11, 1, 12, 13]
Número total de Autores: 13
Afiliação do(s) autor(es):
Mostrar menos -
[1] Univ Connecticut, Dept Chem, Storrs, CT 06269 - USA
[2] Univ Fed Sao Carlos, Dept Chem, BR-13565905 Sao Carlos, SP - Brazil
[3] Univ Hartford, Dept Chem, Hartford, CT 06117 - USA
[4] Univ Coll Cork, Sch Math Sci, Cork T12 YT20 - Ireland
[5] Univ Connecticut, Dept Stat, Storrs, CT 06269 - USA
[6] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4 - Ireland
[7] Univ Coll Dublin, UCD Sch Med & Med Sci, Dublin 4 - Ireland
[8] George Washington Univ, Dept Urol, Washington, DC 20037 - USA
[9] George Washington Univ, Dept Pharmacol & Physiol, Washington, DC 20037 - USA
[10] GW Canc Ctr, Washington, DC 20052 - USA
[11] Univ Connecticut, Inst Mat Sci, Storrs, CT 06269 - USA
[12] Natl Univ Ireland Galway, Sch Chem, Galway H91 CF50 - Ireland
[13] UConn Hlth Ctr, Dept Surg, Farmington, CT 06232 - USA
Número total de Afiliações: 13
Tipo de documento: Artigo Científico
Fonte: Analytical Chemistry; v. 93, n. 2, p. 1059-1067, JAN 19 2021.
Citações Web of Science: 0
Resumo

The inability to distinguish aggressive from indolent prostate cancer is a longstanding clinical problem. Prostate specific antigen (PSA) tests and digital rectal exams cannot differentiate these forms. Because only similar to 10% of diagnosed prostate cancer cases are aggressive, existing practice often results in overtreatment including unnecessary surgeries that degrade patients' quality of life. Here, we describe a fast microfluidic immunoarray optimized to determine 8-proteins simultaneously in 5 mu L of blood serum for prostate cancer diagnostics. Using polymeric horseradish peroxidase (poly-HRP, 400 HRPs) labels to provide large signal amplification and limits of detection in the sub-fg mL(-1) range, a protocol was devised for the optimization of the fast, accurate assays of 100-fold diluted serum samples. Analysis of 130 prostate cancer patient serum samples revealed that some members of the protein panel can distinguish aggressive from indolent cancers. Logistic regression was used to identify a subset of the panel, combining biomarker proteins ETS-related gene protein (ERG), insulin-like growth factor-1 (IGF-1), pigment epithelial-derived factor (PEDF), and serum monocyte differentiation antigen (CD-14) to predict whether a given patient should be referred for biopsy, which gave a much better predictive accuracy than PSA alone. This represents the first prostate cancer blood test that can predict which patients will have a high biopsy Gleason score, a standard pathology score used to grade tumors. (AU)

Processo FAPESP: 17/24053-7 - Desenvolvimentos de métodos eletroquímicos simples para a detecção de biomarcadores visando o diagnóstico de doenças
Beneficiário:Ronaldo Censi Faria
Linha de fomento: Auxílio à Pesquisa - Regular